Larimar Therapeutics Inc. (LRMR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Larimar Therapeutics Inc. (LRMR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.29

-0.19 (-5.46%)

At close: Jan 14, 2025, 3:59 PM

3.29

-0.15%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3.1
Market Cap	210.24M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.09
PE Ratio (ttm)	-3.02
Forward PE	n/a
Analyst	Buy

Ask	3.77
Volume	337,760
Avg. Volume (20D)	839,536
Open	3.53
Previous Close	3.48
Day's Range	3.24 - 3.53
52-Week Range	3.01 - 13.68
Beta	undefined

About LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 19, 2014

Employees 42

Stock Exchange NASDAQ

Ticker Symbol LRMR

Website https://www.larimartx.com

Analyst Forecast

According to 8 analyst ratings, the average rating for LRMR stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 476.63% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-21.72%

Larimar Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

2 months ago · Source

+8.74%

Larimar Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

News

1 week ago · seekingalpha.com

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels f...

4 weeks ago · benzinga.com

What's Going On With Larimar Therapeutics Stock On Tuesday?

On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered...

4 weeks ago · https://thefly.com

Market 'misinterpreting' Larimar data, selloff 'overdone,' says Citi

Citi analyst Samantha Semenkow notes Larimar Therapeutics announced initial data from the ongoing long-term Open Label Extension study evaluating daily subcutaneous injections of 25 mg of nomlabofusp ...

4 weeks ago · benzinga.com

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

2 months ago · zacks.com

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

2 months ago · zacks.com

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

2 months ago · zacks.com

Wall Street Analysts Think Larimar (LRMR) Could Surge 192.89%: Read This Before Placing a Bet

The mean of analysts' price targets for Larimar (LRMR) points to a 192.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

3 months ago · benzinga.com

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.